{"url_path":"/sec/ktta/10-q/2026/item-2","section_key":"item-2","section_title":"Item 2 Unregistered Sales of Equity Securities and Use of Proceeds","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1841330/0001213900-26-057837-index.html","accession_number":"0001213900-26-057837","cik":"0001841330","ticker":"KTTA","issuer_name":"Pasithea Therapeutics Corp.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1841330/0001213900-26-057837-index.html","primary_entity_key":"0001841330","primary_entity_name":"Pasithea Therapeutics Corp."},"word_count":126,"has_tables":true,"body_markdown":"Item 2. Unregistered Sales of Equity Securities and Use of Proceeds\n\n \n\nOn May 1, 2026, we issued to a consultant a warrant to purchase up\nto 15,000 shares of common stock, which warrant has an exercise price equal to $0.841 per share, and one-third of which shall vest 12\nmonths after its date of issuance with the remainder vesting in equal tranches quarterly for two years thereinafter, and shall expire\nten years from its date of issuance. Notwithstanding the foregoing, the purchase rights represented by such warrant shall become fully\nexercisable upon the consummation of a Change in Control (as defined therein). Such warrant was issued in reliance upon the available\nexemptions from registration requirements of Section 4(a)(2) of the Securities Act of 1933, as amended."}